28th Annual North American Cystic Fibrosis Conference

Oct 9, 2014 ‐ Oct 11, 2014



The synchronized sessions from the 2014 NACFC are NOW AVAILABLE!

Full NACFC registrants have complimentary access to the recordings of the 2014 NACFC Plenary sessions, Symposia and Workshops.

Short Course presentations held on Wednesday, October 8, are also available for an additional fee. To purchase access to the Short Course presentations, click here.


Sessions

S01: CFTR: Potentiator Action: Not an Open & Shut Case

Oct 9, 2014 2:00pm ‐ Oct 9, 2014 3:50pm

This session will review our understanding of potentiator mechanism of action and compare the effects that potentiators, such as ivacaftor (VX-770), have on different mutant CFTR proteins. Conclusions that allow for determination of candidates for current potentiator therapies will be drawn. Differences in mutant and wild-type CFTR thermal sensitivity will be discussed. Finally, the impact of potentiators on CFTR correction will be addressed.

Speaker(s):
Standard: $49.99

S02: APP&D: Airway Innate Defense & CFTR

Oct 9, 2014 2:00pm ‐ Oct 9, 2014 3:50pm

This session focuses on mucosal defense in the airways and its regulation by epithelium-derived factors. Presenters will discuss the following: how airway mucins and airway surface liquid contribute to the maintenance of barrier and immune defenses, the physiological mechanisms that control their homeostatic functions, and the pathophysiological consequences of their dysfunction in CF.

Speaker(s):
Standard: $49.99

S03: NT: Outcome Measures With a Focus on Young Children With CF

Oct 9, 2014 2:00pm ‐ Oct 9, 2014 3:50pm

This session will provide insight into outcomes for assessment of early lung disease in cystic fibrosis. It will highlight those outcomes with greatest potential for use in early intervention trials, those best for detecting early disease and those suited to monitoring progress. As knowledge about the nature of early lung disease accumulates, this information is crucial if we are to intervene to prevent the early onset and progression of lung disease in CF.

Speaker(s):
Standard: $49.99

S04: INF/MIC: Bacterial Adaptation & Persistence in the CF Lung

Oct 9, 2014 2:00pm ‐ Oct 9, 2014 3:50pm

The goal of this session is to define the contribution of pathogen diversity and host response to the persistence of bacterial respiratory infections in CF. How these processes impact treatment success or failure will be discussed. The topic of targeting biofilms and persisters in this environment will also be examined.

Speaker(s):
Standard: $49.99

S05: CLIN: The Liver-Gut Axis in CF

Oct 9, 2014 2:00pm ‐ Oct 9, 2014 3:50pm

CF liver disease develops early in childhood and is the second most severe organ complication in CF. This seminar will provide knowledge about the current understanding of CFLD pathogenesis and presents insights about the possible role of intestinal dysbiosis in CFLD. The aim is to identify new areas of CF research and to ignite discussion about possible future treatment strategies for CFLD. Further, a state-of-the-art review about the pathophysiology, clinical presentation and natural course of the disease is directed to all CF caregivers to increase their skills in diagnosing and managing CFLD and complication in CF patients.

Speaker(s):
Standard: $49.99

S06: CLIN: Complications of Treatment

Oct 9, 2014 2:00pm ‐ Oct 9, 2014 3:50pm

This session aims to educate attendees on several important clinical topics that can face people with CF. The first talk covers the diagnosis, prevention and management of venous thromboembolism in CF, as well as the potential difficulties of anticoagulant treatment. The second talk discusses strategies to identify, prevent and manage acute kidney injury, chronic kidney disease and hearing loss in CF. The third talk addresses the challenging area of antibiotic allergy and desensitization in CF. The fourth talk covers the scenario where people with CF develop non-CF disease and the difficulties that can arise when the treatment for one condition impacts on the other.

Speaker(s):
Standard: $49.99

S07: NRS: What About Me? Fertility & Sexuality Issues for Emerging Adults & Men With CF

Oct 9, 2014 2:00pm ‐ Oct 9, 2014 3:50pm

This session will focus on issues surrounding males with CF as relates to sexuality and reproductive health from differing perspectives. We will explore the essential steps leading to planned fatherhood; examine issues involved in males making reproductive decisions; examine how the CF care team can address male sexual and reproductive health issues; and gain insight into reproductive and sexuality issues to improve comprehensiveness of care.

Speaker(s):
Standard: $49.99

P1: Scaling the Mountain: The Journey to Delivering Transformational CF Therapeutics

Oct 9, 2014 4:20pm ‐ Oct 9, 2014 6:00pm

This plenary session will review key CF scientific findings from the past year including review of the results of several key CF clinical trials. We will then discuss future directions for CF therapies, with a focus on the future plans for CFTR modulators.

Speaker(s):
Standard: $49.99

P2: CF Microbiology Past, Present, Future

Oct 10, 2014 9:00am ‐ Oct 10, 2014 10:00am

The microbiology of airway infection in CF has been an area of intense investigation for the past several decades. This session will review the key milestones in CF microbiology during this time, highlight current areas of investigation and discuss emerging concepts and technologies that hold promise to further advance our understanding of the role of infection in the pathology of lung disease in CF. At the completion of this session, participants will have a more complete understanding of what airway microbiology has taught us about CF lung disease progression, how this impacts current treatment strategies and how new technologies have potential to alter current therapy.

Speaker(s):
Standard: $49.99

S13: SW/PSYCH: CFF/ECFS Recommendations of the International Guidelines Committee on Mental Health in CF

Oct 10, 2014 10:30am ‐ Oct 10, 2014 12:20pm

CFF & ECFS have sponsored an International Guidelines Committee on mental health in CF. This session will present the proposed guidelines on screening patients and caregivers for depression and anxiety. Our proposed recommendations include screening individuals with CF ages 12 through adulthood and caregivers of children with CF birth to 17 years. We have recommended specific screening tools, as well as evidence-based psychological and pharmacological interventions. We will present the results of an international survey of health care providers which asked about current screening practices, availability of mental health professionals, and infrastructure needs for implementation.

Speaker(s):
Standard: $49.99
Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content
token-speaker-name image
token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content